Purple Biotech (PPBT) announced the appointment of Dr. Yael Margolin as an independent member of the Company’s Board of Directors. Since 2019, Dr. Margolin has served as a board member to several public and private companies in the healthtech industry, including: Point Biopharma Global (PNT), Scinai Immunotherapeutics (SCNI), Quris AI, MakeSense, Neovac, Welltech Ventures, Ramot at Tel Aviv University and TAU Ventures by Tel Aviv University. In addition, Purple announces that Fabien Sebille, who served as the Company’s Chief Business Officer, CBO, resigned from such position to pursue other opportunities as of the end of November 2023.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PPBT:
- Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
- Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
- Purple Biotech completes patient enrollment in Phase 2 pancreatic cancer trial
- Purple Biotech reports Q3 EPS (23c), consensus (23c)
- Purple Biotech Reports Third Quarter 2023 Financial Results